Skip to main content
. 2020 Nov 25;14:603647. doi: 10.3389/fnins.2020.603647

FIGURE 2.

FIGURE 2

Targeted therapies in glioblastoma (GBM). The introduction of novel targeted therapies has been allowed by the comprehensive characterization of the molecular landscape of somatic genomic alterations identifying a series of mutated genes and abnormal rearrangements potentially utilizable as therapeutic targets.